Q-omics provides the consensus-scored MYO1B profile across patient tissues and cancer cell-line models. MYO1B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MYO1B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, MYO1B protein abundance shows 22,628 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, and HNSC as cancer lineages where MYO1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO1B survival associations across molecular data types. MYO1B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO1B RNA expression–survival associations across cancer types. High MYO1B expression shows unfavorable associations in MESO, KIRP, HNSC, UVM, STAD and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MYO1B RNA expression.
This table summarizes MYO1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYO1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO1B shows lower tumor expression in LUAD, KICH and LUSC and higher tumor expression in HNSC, STAD and COAD. The HNSC box plot shows higher MYO1B RNA expression in tumor versus normal tissue (log2 FC = +2.785, t-test p < 0.001).
This table shows molecular features associated with MYO1B in patient tissues and cancer cell lines. In patient samples, MYO1B shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
